These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 9324177)

  • 1. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K; Dudley MN; Posner MR; Darnowski J
    Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
    J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
    Howell JD; Warren HW; Anderson JH; Kerr DJ; McArdle CS
    Eur J Surg; 1999 Jul; 165(7):652-8. PubMed ID: 10452259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of 5-fluorouracil and its penetration into pancreatic juice in dogs.
    Zhu Z; Fu Q; Nightingale CH; Zhao YP; Liao Q; Wang HN; Xue CQ; Yang ZY; Li DK
    Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):7-9. PubMed ID: 10375748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
    Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2).
    Joulia JM; Pinguet F; Ychou M; Duffour J; Topart D; Grosse PY; Astre C; Bressolle F
    Anticancer Res; 1997; 17(4A):2727-30. PubMed ID: 9252705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
    Joulia JM; Pinguet F; Ychou M; Duffour J; Astre C; Bressolle F
    Eur J Cancer; 1999 Feb; 35(2):296-301. PubMed ID: 10448274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.